$97.930
-3.731 (-3.81%)At close
MANE News
MANE Events
Veradermics Achieves Significant Progress with VDPHL01
"In the second quarter of 2026, we made significant advancements in the development of VDPHL01 for female pattern hair loss, supporting key milestones for the program. The positive Phase 2 results from Study '207' marked the first successful clinical demonstration of an oral treatment for female pattern hair loss in the United States and increased our conviction in VDPHL01 as a potential treatment for women as we advance toward registration-directed topline data from the now fully enrolled Phase 2/3 Study '306' in the first half of 2027," said Reid Waldman, CEO. "With enrollment in Study '306' now complete, we look forward to a catalyst-rich remainder of 2026 as we progress toward topline data from the confirmatory Phase 3 Study '304' in men and 12-month data from Study '302', both anticipated in the second half of 2026. Veradermics remains well capitalized to execute against these milestones while continuing preparations for a potential commercial launch, with the goal of establishing VDPHL01, if approved, as a foundational treatment for women and men living with pattern hair loss."
Veradermics Raises $472 Million in Follow-On Offering
Cash, cash equivalents, and marketable securities totaled $819.9 million as of June 30, 2026 including net proceeds from our follow-on offering completed in the second quarter 2026. Veradermics raised approximately $472.0 million in aggregate gross proceeds in May 2026 through its follow-on offering and concurrent private placement subsequent to the initial public offering in February of 2026. These proceeds, together with existing cash, cash equivalents and marketable securities, are expected to support Veradermics' current operating plans into 2030, including multiple anticipated Phase 3 readouts and the potential commercial launch of VDPHL01, if approved.
Selling Stockholders Plan to Sell Up to 16.77M Shares
This filing relates to the offer and sale from time to time by the selling stockholders of up to 16.77M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
Veradermics Presents VDPHL01 Study Data
Veradermics announced the presentation of data from the Phase 2/3 Study '302' of VDPHL01 in male patients with mild-to-moderate pattern hair loss. The subgroup analysis data were shared in a poster presentation on July 16, and will be shared in an oral presentation on July 17, during the 2026 American Academy of Dermatology Innovation Academy in New York City. Study '302' is a randomized, double-blind, placebo-controlled Phase 2/3 trial evaluating treatment with VDPHL01, a proprietary extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss. The new data include results from an age-based subgroup analysis of the efficacy and safety of VDPHL01 in males less than 40 years of age and males 40 years of age and older. VDPHL01 is currently being evaluated in an extensive development program designed to support the approval of VDPHL01 in both male and female pattern hair loss. In April 2026, Veradermics announced topline results from Study '302' in male pattern hair loss and, in February 2026, Veradermics announced enrollment completion in its second Phase 3 male trial, Study '304,' with topline results anticipated in 2H 2026. Earlier this week, Veradermics announced topline data in females with pattern hair loss from Study '207' and that topline data are anticipated from Study '306,' a registration-directed Phase 2/3 trial in females with pattern hair loss, in 1H 2027.
Veradermics Stock Rises 13.9% to $125.52
Veradermics is up 13.9%, or $15.35 to $125.52.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.